EvaluatePharma - Chugai Selected Reports

Chugai

To see an up-to date selection of historical analyses and insights on Chugai, visit our new, dynamically updated Company Summary report pages for Chugai.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma^®.

How to access FREE content

Search the content using the search box at the top of every page
Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

A small selected sample of reports and related news headlines for Chugai are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Chugai, or on any other Company covered by EvaluatePharma^® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)

Romark Initiates Clinical Trial of Alinia for Treatment of Influenza	(Romark Laboratories)	(Invalid Date)
ACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Approved in the United States for Rheumatoid Arthritis	(Chugai)	(Invalid Date)
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis	(Roche)	(Invalid Date)
Prophylaxis of Influenza in Infants and Children Approved as an Additional Indication of Anti-influenza Drug Tamiflu®	(Chugai)	(Invalid Date)
Greater Chances of Cure for Patients with HER2-Positive Early Breast Cancer When Treated With One Year of Herceptin	(Roche)	(Invalid Date)
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)	(Roche)	(Invalid Date)
Recombinant Human Erythropoietin, Epogin® Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia	(Chugai)	(Invalid Date)
Anti-Malignancy Agent Avastin® Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer	(Chugai)	(Invalid Date)
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative	(Chugai)	(Invalid Date)
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative	(Taisho Pharmaceutical)	(Invalid Date)
Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission	(Roche)	(Invalid Date)
ACTEMRA Inhibits Progression of Joint Destruction in RA Patients by Over 80% Compared to Methotrexate Alone	(Chugai)	(Invalid Date)
ACTEMRA Inhibits Progression of Joint Destruction in RA Patients by Over 80% Compared to Methotrexate Alone	(Roche)	(Invalid Date)
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin®	(Chugai)	(Invalid Date)
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis	(Roche)	(Invalid Date)
Anti-Cancer Agent Xeloda® and Avastin® Obtained Approval for Additional Indication of Colorectal Cancer	(Chugai)	(Invalid Date)
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva®	(Chugai)	(Invalid Date)
Two New Studies Report Increased Survival Rates in Tamiflu-treated Patients With Avian Flu (H5N1) and Severe Seasonal Flu	(Roche)	(Invalid Date)
FDA Accepts Complete Response Resubmission for ACTEMRA (tocilizumab)	(Roche)	(Invalid Date)
Chugai Files NDA for a Renal Anemia Agent R744	(Chugai)	(Invalid Date)
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin® in Chemotherapy Induced Anemia	(Chugai)	(Invalid Date)
New Data Reinforces Long-Term Efficacy of ACTEMRA in Rheumatoid Arthritis Across All Patient Population Types	(Roche)	(Invalid Date)
Herceptin Landmark Study (ToGA) Reveals Unprecedented Survival Benefit in HER2-Positive Stomach Cancer	(Roche)	(Invalid Date)
Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer	(OSI Pharmaceuticals)	(Invalid Date)
Two-Year Data Reinforce Effectiveness of ACTEMRA in Inhibiting Joint Damage and Improving Physical Function in Patients With Rheumatoid Arthritis	(Roche)	(Invalid Date)
Approval of Partial Change of API Manufacturing Method and Pharmaceutical Formulation of the Recombinant Human Erythropoietin "Epogin® Injection"	(Chugai)	(Invalid Date)

EvaluatePharma^® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma^® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma^®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma^® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.